The purpose of the study was to investigate the role of transforming growth factor-β1 in the formation of pathological remodeling of the left ventricle of the heart in patients with arterial hypertension with and without type 2 diabetes mellitus against the background of abdominal obesity. Materials and methods. 58 patients with arterial hypertension of the II stage, 2-3 degree with abdominal obesity of the I-III degree were involved in the examination, of which 32 had type 2 diabetes. The control group consisted of 14 healthy people. Structural indicators of the heart were studied using an echocardiographic study. Determination of the level of transforming growth factor-β1 in blood serum was carried out by the immunoenzymatic method. Results and discussion. It was established that in the groups of patients with arterial hypertension with type 2 diabetes mellitus and abdominal obesity and arterial hypertension with abdominal obesity, probable differences in transforming growth factor-β1 between types of cardiac remodeling were not detected. Probable differences in the levels of transforming growth factor-β1 in CGLS and EGLS were established only between the groups of the examined and probably differed from the control group, which indicates a significant influence of abdominal obesity on the development of adverse remodeling, both in arterial hypertension with type 2 diabetes mellitus and with arterial hypertension without it. However, the most pronounced changes in transforming growth factor-β1 were observed in subjects with impaired carbohydrate metabolism (type 2 diabetes mellitus), which allows us to consider hyperglycemia as an additional factor in the formation of pathological geometry of the heart. Conclusion. The data obtained as a result of the study may indicate that in the formation of pathological types of cardiac remodeling in patients with arterial hypertension with abdominal obesity, from the point of view of the development of interstitial fibrosis, a significant contribution belongs to the transforming growth factor-β1, which is a key factor in the formation of hypertrophy of the myocardium of the left ventricle. Along with this, additional factors of the formation of cardiac remodeling should be noted in case of violation of carbohydrate metabolism in arterial hypertension with type 2 diabetes mellitus on the background of abdominal obesity. The association of a probable increase in the levels of transforming growth factor-β1 in concentric hypertrophy of the left ventricle and eccentric hypertrophy of the left ventricle and the consequences of hyperglycemia significantly increases the cardiovascular risk, which determines the expediency of earlier therapeutic intervention

Keywords: transforming growth factor-β1, arterial hypertension, diabetes mellitus, abdominal obesity, cardiac remodeling

Full text: PDF (Ukr) 251K

1. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-3104. PMID: 30165516. https://doi.org/10.1093/eurheartj/ehy339
2. Koval SM. Problemy klasyfikatsiyi i diahnostyky arterialnoi hipertenziyi ta stratyfikatsiyi ryzyku rozvytku yiyi uskladnen v svitli Yevropeyskykh rekomendatsiy 2018 roku(komentar do rekomendatsiy) [Problems of classification and diagnosis of arterial hypertension and risk stratification of the development of its complications in the light of the European recommendations of 2018 (commentary on the recommendations)]. Arterialna hipertenziya. 2019;1(63):33-41. [Ukrainian]
3. Koval SM, Yushko KO. Tsukrovyi diabet 2-ho typu ta sertsevo-sudynni zakhvoryuvannya. Chastyna I. Vyznachennya problemy, stratyfikatsiya kardiovaskulyarnoho ryzyku i osnovni napryamky profilaktyky sertsevo-sudynnykh zakhvoryuvan u khvorykh na tsukrovyi diabet 2-ho typu [Type 2 diabetes and cardiovascular disease. Part I. Definition of the problem, stratification of cardiovascular risk and the main directions of prevention of cardiovascular diseases in patients with type 2 diabetes]. Arterialna hipertenziya. 2020;5:17-25. [Ukrainian]
4. Ena LM, Bevzyuk LV. Rol hemodynamycheskykh y humo¬ralnykh faktorov v patoheneze myokardyalnoho fybroza u patsyentov pozhyloho vozrasta s arteryalnoy hypertenzyey y fybryllyatsyey predserdyi (obzor lyteratury) [The role of hemodynamic and humoral factors in the pathogenesis of myocardial fibrosis in elderly patients with arterial hypertension and atrial fibrillation (literature review).] Problema Starenyya y Dolholetyya. 2013;22(4):365-79. [Russian]
5. Verrecchia F, Mauviel A. Transfoming growth factor-beta and fibrosis. World J Gastroenterol. 2007;47(8):13-18. PMID: 17589920. PMCID: PMC4172611. https://doi.org/10.3748/wjg.v13.i22.3056
6. Seeland U, Haeuseler C, Hinrichs R, Rosenkranz S, Pfitzner T, Scharffetter-Kochanek K, et al. Myocardial fibrosis in transforming growth factor-b1 (TGF-b1) transgenic mice is associated with inhibition of interstitial collagenase Eur J Clin Invest. 2002;32:295-303. PMID:12027867. https://doi.org/10.1046/j.1365-2362.2002.00985.x
7. Koval SN, Reznyk LA, Starchenko TH, Yushko KA. Assotsyatsyya profybrozyruyushcheho faktora-transformyruyushcheho faktora rosta β-1 s dyastolycheskoy dysfunktsyey levoho zheludochka u bolnykh arteryalnoy hypertenzyey pry ee yzolyrovannom techenyi y pry sochetanyi s sakharnym dyabetom 2 typa [Association of profibrosing factor-transforming growth factor β-1 with diastolic dysfunction of the left ventricle in patients with arterial hypertension in its isolated course and in combination with type 2 diabetes mellitus]. Materialy naukovo-praktychnoi konferentsiyi z mizhnarodnoyu uchastyu “Dosyahnennya ta perspektyvy eksperymentalnoi ta klinichnoi endokrynolohiyi (Devyatnadtsyati Danylevski chytannya)”; Kharkiv 2020. 2020. p. 79-80. [Russian]
8. WHO. Obesity: Prevention and managing the global epidemic. Technical Report Series 894. Geneva: WHO; 2000.
9. Svіshchenko EP Bezrodna LV, Mіshchenko LA, Sіrenko YuM, Kupchins'ka OG, Radchenko GD. Klіnіchnij protokol nadannya medichnoi dopomogi pacіentam іz gіpertonіchnoyu hvoroboyu (esencіal'noyu AG). Sercevo-sudinnі zahvoryuvannya. Klasifіkacіya, standarti dіagnostiki ta lіkuvannya [Clinical Protocol for Medical Assistance to Patients with Hypertonic Disease (Essential AG). Cardiovascular disease. Classification, diagnostic and treatment standards]. Eds by VM Kovalenko, MІ Lutayi, YuM Sіrenko, OS Sichov. K: MORІON; 2016. s. 59-63. [Ukrainian]
10. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7(2):79-108. PMID: 16458610. https://doi.org/10.1016/j.euje.2005.12.014
11. Fadyeyenko HD, Kushnir IE, Chernova VM, Solomentseva TA, Kurinna OH, Nikiforova YaV, et al. Vzayemozv'yazok mizh rivnem syrovatkovykh markeriv zapalennya ta metabolichnymy porushennyamy pry nealkoholniy zhyroviy khvorobi pechinky [The relationship between the level of serum markers of inflammation and metabolic disorders in non-alcoholic fatty liver disease]. Suchasna hastroenterolohiya. 2018;5:7-12. [Ukrainian]
12. Kyrychenko NM. Rivni biomarkeriv systemnoho zapalennya u zhinok z arterialnoyu hipertenziyeyu ta ozhyrinnyam v zalezhnosti vid nayavnosti suputnoho tsukrovoho diabetu 2 typu [Levels of biomarkers of systemic inflammation in women with arterial hypertension and obesity depending on the presence of concomitant type 2 diabetes] Skhidnoyevropeyskyi zhurnal vnutrishnoi ta simeynoi medytsyny. 2020;1:43-46. [Ukrainian]. https://doi.org/10.15407/internalmed2020.01.043
13. Tu, W Z, Fu YB, Xie X. RepSox, a small molecule inhibitor of the TGFβ receptor, induces brown adipogenesis and browning of white adipocytes. Acta Pharmacologica Sinica. 2019;40(12):1523-1531. PMID: 31235818. PMCID: PMC7471457. doi:10.1038/s41401-019-0264-2
14. Sciarretta S, Ferrucci A, Ciavarella GM, et al. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertension. 2007;20(7):784-791. PMID: 17586414. https://doi.org/10.1016/j.amjhyper.2007.01.023
15. Kalupahana NS, Moustaid-Moussa N. The renin-angiotensin system:a link between obesity, inflammation and insuline resistence. Obes Rew. 2012;13(2):136-139. PMID: 22034852. doi.org/10.1111/j.1467-789X.2011.00942.x
16. Uría JA, Jiménez MG, Balbín M, Freije JM, López-Otín C. Differential Effects of Transforming Growth Factor-β1 on the Expression of Collagenase-1 and Collagenase-3 in Human Fibroblasts. Biol Chem. 1998;273:9697-9777. PMID: 9545314. doi.org/10.1074/jbc.273.16.9769
17. Belovol AN, Knyazkova II. Kletochnye, molekulyarnye i strukturnye mekhanizmy remodelirovaniya LZh pri serdechnoy nedostatochnosti [Cellular, molecular and structural mechanisms of LV remodeling in heart failure]. Prakticheskaya Anhiolohiya. 2013;4(63):53-65. [Russian]